Heightened interest in tricuspid regurgitation (TR) stems from the consistent association of
mortality with greater severity of TR, and a low use of surgical solutions in the setting of high …

As populations age worldwide, the burden of valvular heart disease has grown
exponentially, and so has the proportion of affected women. Although rheumatic valve …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive review was conducted on literature published through March 1, 2020. Searches …

Valvular regurgitation represents an important cause of cardiovascular morbidity and
mortality. Imaging is pivotal in the evaluation of native valve regurgitation and …

The “Guidelines on the Management of Valvular Heart Disease” were initially published as
the “Guidelines on Non-pharmacological Treatment of Valvular Heart Disease” in 2002 …

Aims Tricuspid regurgitation (TR) is associated with high morbidity and mortality rates with
limited treatment options. We report one-and two-year outcomes of the Cardioband tricuspid …

Interest in the pathophysiology, etiology, management, and outcomes of patients with
tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing …

Aims Atrial functional tricuspid regurgitation (A-FTR) is a recently defined phenotype of
functional tricuspid regurgitation (FTR) associated with persistent/permanent atrial …

Tricuspid regurgitation (TR) is a highly prevalent valvular heart disease and is associated
with an increased risk of cardiovascular events and death at long‐term follow‐up. Functional …

Transcatheter tricuspid valve interventions (TTVIs) comprise a variety of catheter-based
interventional techniques for treatment of tricuspid regurgitation (TR) in patients at high …